Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 11/2019

01.11.2019 | STATE-OF-THE-ART Review

Vasopressor therapy in critically ill patients with shock

verfasst von: James A. Russell

Erschienen in: Intensive Care Medicine | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Vasopressors are administered to critically ill patients with vasodilatory shock not responsive to volume resuscitation, and less often in cardiogenic shock, and hypovolemic shock.

Objectives

The objectives are to review safety and efficacy of vasopressors, pathophysiology, agents that decrease vasopressor dose, predictive biomarkers, β1-blockers, and directions for research.

Methods

The quality of evidence was evaluated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE).

Results

Vasopressors bind adrenergic: α1, α2, β1, β2; vasopressin: AVPR1a, AVPR1B, AVPR2; angiotensin II: AG1, AG2; and dopamine: DA1, DA2 receptors inducing vasoconstriction. Vasopressor choice and dose vary because of patients and physician practice. Adverse effects include excessive vasoconstriction, organ ischemia, hyperglycemia, hyperlactatemia, tachycardia, and tachyarrhythmias. No randomized controlled trials of vasopressors showed a significant difference in 28-day mortality rate. Norepinephrine is the first-choice vasopressor in vasodilatory shock after adequate volume resuscitation. Some strategies that decrease norepinephrine dose (vasopressin, angiotensin II) have not decreased 28-day mortality while corticosteroids have decreased 28-day mortality significantly in some (two large trials) but not all trials. In norepinephrine-refractory patients, vasopressin or epinephrine may be added. A new vasopressor, angiotensin II, may be useful in profoundly hypotensive patients. Dobutamine may be added because vasopressors may decrease ventricular contractility. Dopamine is recommended only in bradycardic patients. There are potent vasopressors with limited evidence (e.g. methylene blue, metaraminol) and novel vasopressors in development (selepressin).

Conclusions

Norepinephrine is first choice followed by vasopressin or epinephrine. Angiotensin II and dopamine have limited indications. In future, predictive biomarkers may guide vasopressor selection and novel vasopressors may emerge.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Annane D, Ouanes-Besbes L, de Backer D, Du B, Gordon AC, Hernandez G et al (2018) A global perspective on vasoactive agents in shock. Intensive Care Med 44(6):833–846PubMedCrossRef
2.
Perner A, Gordon AC, Angus DC, Lamontagne F, Machado F, Russell JA et al (2017) The intensive care medicine research agenda on septic shock. Intensive Care Med 43(9):1294–1305PubMedCrossRef
3.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45(3):486–552PubMedCrossRef
4.
de Grooth HJ, Postema J, Loer SA, Parienti JJ, Oudemans-van Straaten HM, Girbes AR (2018) Unexplained mortality differences between septic shock trials: a systematic analysis of population characteristics and control-group mortality rates. Intensive Care Med 44(3):311–322PubMedPubMedCentralCrossRef
5.
6.
Vail EA, Gershengorn HB, Hua M, Walkey AJ, Wunsch H (2016) Epidemiology of vasopressin use for adults with septic shock. Ann Am Thorac Soc 13(10):1760–1767PubMedPubMedCentral
7.
Russell JA (2019) Shock syndromes related to sepsis. In: Chapter 100 in 26th edition Goldman-Cecil Textbook of Medicine (in press)
8.
Asfar P, Teboul JL, Radermacher P (2014) High versus low blood-pressure target in septic shock. N Engl J Med 371(3):283–284PubMed
9.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368–1377PubMedCrossRef
10.
Angus DC (2017) Early, goal-directed therapy for septic shock—a patient-level meta-analysis. N Engl J Med 377(10):995PubMed
11.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8):801–810PubMedPubMedCentralCrossRef
12.
Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877–887PubMedCrossRef
13.
Russell JA, Lee T, Singer J, Boyd JH, Walley KR et al (2017) The septic shock 3.0 definition and trials: a vasopressin and septic shock trial experience. Crit Care Med 45(6):940–948PubMedCrossRef
14.
Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A et al (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8):762–774PubMedPubMedCentralCrossRef
15.
Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M et al (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316(5):509–518PubMedCrossRef
16.
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H et al (2017) Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377(5):419–430PubMedCrossRef
17.
Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S et al (2018) Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378(9):809–818PubMedCrossRef
18.
Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7):862–871PubMedCrossRef
19.
Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2):111–124PubMedCrossRef
20.
Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378(9):797–808PubMedCrossRef
21.
Russell JA, Vincent JL, Kjolbye AL, Olsson H, Blemings A, Spapen H et al (2017) Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care 21(1):213PubMedPubMedCentralCrossRef
22.
Angus DC, van der Poll T (2013) Severe sepsis and septic shock. N Engl J Med 369(21):2063PubMed
23.
Bucher M, Kees F, Taeger K, Kurtz A (2003) Cytokines down-regulate alpha1-adrenergic receptor expression during endotoxemia. Crit Care Med 31(2):566–571PubMedCrossRef
24.
Nakada TA, Russell JA, Boyd JH, Aguirre-Hernandez R, Thain KR, Thair SA et al (2010) Beta2-adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 181(2):143–149PubMedCrossRef
25.
Nakada TA, Russell JA, Boyd JH, McLaughlin L, Nakada E, Thair SA et al (2011) Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 39(7):1641–1648PubMedCrossRef
26.
Nakada TA, Russell JA, Wellman H, Boyd JH, Nakada E, Thain KR et al (2011) Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 139(5):1042–1049PubMedCrossRef
27.
Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S et al (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32(1):21–30PubMedCrossRef
28.
Moncada S, Higgs A (1993) The l-arginine-nitric oxide pathway. N Engl J Med 329(27):2002–2012PubMedCrossRef
29.
Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP et al (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N Engl J Med 336(13):912–918PubMedCrossRef
30.
Wagner K, Wachter U, Vogt JA, Scheuerle A, McCook O, Weber S et al (2013) Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock. Intensive Care Med Exp 1(1):21PubMedCrossRef
31.
Kanji HD, McCallum J, Sirounis D, MacRedmond R, Moss R, Boyd JH (2014) Limited echocardiography-guided therapy in subacute shock is associated with change in management and improved outcomes. J Crit Care 29(5):700–705PubMedCrossRef
32.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589–1596PubMedCrossRef
33.
Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS et al (2017) Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 376(23):2235–2244PubMedPubMedCentralCrossRef
34.
Komorowski M, Celi LA, Badawi O, Gordon AC, Faisal AA (2018) The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med 24(11):1716–1720PubMedCrossRef
35.
Udy AA, Finnis M, Jones D, Delaney A, Macdonald S, Bellomo R et al (2018) Incidence, patient characteristics, mode of drug delivery, and outcomes of septic shock patients treated with vasopressors in the arise trial. Shock 52(4):400–407
36.
Stolk RF, van der Poll T, Angus DC, van der Hoeven JG, Pickkers P, Kox M (2016) Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am J Respir Crit Care Med 194(5):550–558PubMedCrossRef
37.
Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J et al (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34(12):2226–2234PubMedCrossRef
38.
Van den Berghe G, de Zegher F (1996) Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 24(9):1580–1590PubMedCrossRef
39.
40.
Russell JA, Walley KR (2010) Vasopressin and its immune effects in septic shock. J Innate Immun 2(5):446–460PubMedCrossRef
41.
Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA et al (2017) Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology 126(1):85–93PubMedCrossRef
42.
Fisher J, Douglas JJ, Linder A, Boyd JH, Walley KR, Russell JA (2016) Elevated plasma angiopoietin-2 levels are associated with fluid overload, organ dysfunction, and mortality in human septic shock. Crit Care Med 44(11):2018–2027PubMedCrossRef
43.
Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V et al (2009) Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 13(4):R130PubMedPubMedCentralCrossRef
44.
Liu ZM, Chen J, Kou Q, Lin Q, Huang X, Tang Z et al (2018) Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med 44(11):1816–1825PubMedCrossRef
45.
46.
Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B et al (2001) Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 29(10):1860–1867PubMedCrossRef
47.
Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370(9588):676–684PubMedCrossRef
48.
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362(9):779–789PubMedCrossRef
49.
Russell JA, Wellman H, Walley KR (2018) Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital. J Intensive Care 6:73PubMedPubMedCentralCrossRef
50.
Hammond DA, Ficek OA, Painter JT, McCain K, Cullen J, Brotherton AL et al (2018) Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy 38(5):531–538PubMedCrossRef
51.
Cheng L, Yan J, Han S, Chen Q, Chen M, Jiang H et al (2019) Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials. Crit Care 23(1):168PubMedPubMedCentralCrossRef
52.
Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370(17):1583–1593PubMedCrossRef
53.
Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ (2011) Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 306(20):2248–2254PubMedPubMedCentralCrossRef
54.
Dargent A, Nguyen M, Fournel I, Bourredjem A, Charles PE, Quenot JP et al (2018) Vasopressor cumulative dose requirement and risk of early death during septic shock: an analysis from the EPISS cohort. Shock 49(6):625–630PubMedCrossRef
55.
Russell JA, Fjell C, Hsu JL, Lee T, Boyd J, Thair S et al (2013) Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 188(3):356–364PubMedCrossRef
56.
Dunser MW, Bouvet O, Knotzer H, Arulkumaran N, Hajjar LA, Ulmer H et al (2018) Vasopressin in cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 32(5):2225–2232PubMedCrossRef
57.
Hernandez G, Ospina-Tascon GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J et al (2019) Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA 321(7):654–664PubMedPubMedCentralCrossRef
58.
Wu M, Ghassemi M, Feng M, Celi LA, Szolovits P, Doshi-Velez F (2017) Understanding vasopressor intervention and weaning: risk prediction in a public heterogeneous clinical time series database. J Am Med Inform Assoc 24(3):488–495PubMed
59.
Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311(13):1308–1316PubMedCrossRef
60.
Linder A, Lee T, Fisher J, Singer J, Boyd J, Walley KR et al (2016) Short-term organ dysfunction is associated with long-term (10-year) mortality of septic shock. Crit Care Med 44(8):e728–e736PubMedCrossRef
61.
Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S (2019) Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med 199(9):1097–1105PubMedCrossRef
62.
Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A (2015) Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One 10(8):e0129305PubMedPubMedCentralCrossRef
63.
64.
Dunser MW, Festic E, Dondorp A, Kissoon N, Ganbat T, Kwizera A et al (2012) Recommendations for sepsis management in resource-limited settings. Intensive Care Med 38(4):557–574PubMedPubMedCentralCrossRef
65.
Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H (2017) Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA 317(14):1433–1442PubMedCrossRef
66.
Yamamoto K, Ikeda U, Okada K, Saito T, Kawahara Y, Okuda M et al (1997) Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. Hypertension 30(5):1112–1120PubMedCrossRef
67.
Rudichenko VM, Beierwaltes WH (1995) Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res 32(2):100–105PubMedCrossRef
68.
Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27(8):1416–1421PubMedCrossRef
69.
Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47(4):699–703 (discussion-5) PubMedCrossRef
70.
Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96(3):576–582PubMedCrossRef
71.
Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877–887PubMedCrossRef
72.
Nagendran M, Russell JA, Walley KR, Brett SJ, Perkins GD, Hajjar L et al (2019) Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med 45(6):844–855PubMedCrossRef
73.
Russell JA, Walley KR, Gordon AC, Cooper DJ, Hebert PC, Singer J et al (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37(3):811–818PubMedCrossRef
74.
Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM et al (2010) The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36(1):83–91PubMedCrossRef
75.
Anantasit N, Boyd JH, Walley KR, Russell JA (2014) Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock. Crit Care Med 42(8):1812–1820PubMedCrossRef
76.
Jeon K, Song JU, Chung CR, Yang JH, Suh GY (2018) Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS). Crit Care 22(1):131PubMedPubMedCentralCrossRef
77.
He X, Su F, Taccone FS, Laporte R, Kjolbye AL, Zhang J et al (2016) A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med 44(1):23–31PubMedCrossRef
78.
Maybauer MO, Maybauer DM, Enkhbaatar P, Laporte R, Wisniewska H, Traber LD et al (2014) The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med 42(7):e525–e533PubMedPubMedCentralCrossRef
79.
Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z et al (2014) Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 18(5):534PubMedPubMedCentralCrossRef
80.
Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP et al (2017) Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc 19(1):43–49PubMed
81.
Paciullo CA, McMahon Horner D, Hatton KW, Flynn JD (2010) Methylene blue for the treatment of septic shock. Pharmacotherapy 30(7):702–715PubMedCrossRef
82.
Gordon AC, Wang N, Walley KR, Ashby D, Russell JA (2012) The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest 142(3):593–605PubMedCrossRef
83.
Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375(17):1638–1648PubMedCrossRef
84.
De Backer D, Creteur J, Silva E, Vincent JL (2003) Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 31(6):1659–1667PubMedCrossRef
85.
Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310(16):1683–1691PubMedCrossRef
86.
Liu P, Wu Q, Tang Y, Zhou Z, Feng M (2018) The influence of esmolol on septic shock and sepsis: a meta-analysis of randomized controlled studies. Am J Emerg Med 36(3):470–474PubMedCrossRef
87.
Morimatsu H, Uchino S, Chung J, Bellomo R, Raman J, Buxton B (2003) Norepinephrine for hypotensive vasodilatation after cardiac surgery: impact on renal function. Intensive Care Med 29(7):1106–1112PubMedCrossRef
88.
Vedel AG, Holmgaard F, Rasmussen LS, Langkilde A, Paulson OB, Lange T et al (2018) High-target versus low-target blood pressure management during cardiopulmonary bypass to prevent cerebral injury in cardiac surgery patients: a randomized controlled trial. Circulation 137(17):1770–1780PubMedCrossRef
89.
Argenziano M, Chen JM, Choudhri AF, Cullinane S, Garfein E, Weinberg AD et al (1998) Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 116(6):973–980PubMedCrossRef
90.
Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR et al (1999) Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 18(8):814–817PubMedCrossRef
91.
Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW et al (2000) Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 69(1):102–106PubMedCrossRef
92.
Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR et al (2003) A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 75(3):926–930PubMedCrossRef
93.
Rosenzweig EB, Starc TJ, Chen JM, Cullinane S, Timchak DM, Gersony WM et al (1999) Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 100(19 Suppl):II182–II186PubMed
94.
95.
Hajjar AM, Vincent JL, Galas FRBG, Rhodes A, Landonni G, Osawa EA et al (2016) Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCSS randomized controlled trial. Anesthesiology 126(1):85–93CrossRef
96.
Moller MH, Granholm A, Junttila E, Haney M, Oscarsson-Tibblin A, Haavind A et al (2018) Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 62(4):420–450PubMedPubMedCentralCrossRef
97.
van Diepen S, Thiele H (2019) An overview of international cardiogenic shock guidelines and application in clinical practice. Curr Opin Crit Care 25:365–370PubMedCrossRef
98.
Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G et al (2018) Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 72(2):173–182PubMedCrossRef
99.
Russell JA, Rush B, Boyd J (2018) Pathophysiology of septic shock. Crit Care Clin 34(1):43–61PubMedCrossRef
100.
Spahn, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ et al (2019) The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 23(1):98PubMedPubMedCentralCrossRef
101.
Silversides JA, Fitzgerald E, Manickavasagam US, Lapinsky SE, Nisenbaum R, Hemmings N et al (2018) Deresuscitation of patients with iatrogenic fluid overload is associated with reduced mortality in critical illness. Crit Care Med 46(10):1600–1607PubMedCrossRef
Metadaten
Titel
Vasopressor therapy in critically ill patients with shock
verfasst von
James A. Russell
Publikationsdatum
01.11.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 11/2019
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-019-05801-z

Weitere Artikel der Ausgabe 11/2019

Intensive Care Medicine 11/2019 Zur Ausgabe

Imaging in Intensive Care Medicine

Camel shape in transpulmonary thermodilution monitoring

Editorial

“Hang on, I haven’t seen this patient yet…”: near simultaneous admissions to the ICU

Letter

Highly prolific authors in critical care: which factors influence their scientific output?

Less is more in Intensive Care

Endotracheal tube management during mechanical ventilation: less is more!

Editorial

Intensive care medicine rapid practice guidelines (ICM-RPG): paving the road of the future

What's New in Intensive Care

Electrically generated nitric oxide from air: a safe and economical treatment for pulmonary hypertension

Neu im Fachgebiet AINS

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

11.04.2024 | Rückenschmerzen | Nachrichten

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren